When when _老虎社区_美港股上老虎

2021-10-18

When when when... [看涨] [看涨] [看涨]

Clover Health Stock Has an Outside Chance of Suprising in Its Upcoing Earnings

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":850176352,"tweetId":"850176352","gmtCreate":1634567747484,"gmtModify":1634567751594,"author":{"id":3573033041140696,"idStr":"3573033041140696","authorId":3573033041140696,"authorIdStr":"3573033041140696","name":"Wayne77","avatar":"https://static.tigerbbs.com/67d3224987d29dfccad80b3fe4074912","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>When when when...&nbsp;[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;</body></html>","htmlText":"<html><head></head><body>When when when...&nbsp;[看涨]&nbsp;[看涨]&nbsp;[看涨]&nbsp;</body></html>","text":"When when when... [看涨] [看涨] [看涨]","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/850176352","repostId":1114755787,"repostType":4,"repost":{"id":"1114755787","kind":"news","pubTimestamp":1634563405,"share":"https://www.laohu8.com/m/news/1114755787?lang=&edition=full","pubTime":"2021-10-18 21:23","market":"us","language":"en","title":"Clover Health Stock Has an Outside Chance of Suprising in Its Upcoing Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1114755787","media":"InvestorPlace","summary":"Buying CLOV stock is all about whether you think it can start controlling costs.\n\nClover Health Corp","content":"<blockquote>\n Buying CLOV stock is all about whether you think it can start controlling costs.\n</blockquote>\n<a href=\"https://laohu8.com/S/CLOV\">Clover Health Corp</a> stock has few friends on the “buy” side&nbsp;today.\nAccording to the&nbsp;Wall Street Journal,&nbsp;five analysts&nbsp;give shares in the Medicare Advantage provider either a “hold” or “sell” rating, with none of them willing to give it a “buy” rating.\nWorse yet, retail traders haven’t been so keen on it either lately. Even a recent development (which admittedly seems like small potatoes) has failed to give it more than just a slight bump-up in price.\nSo, a lack of Wall Street or Main Street enthusiasm makes it a sell, right? Not exactly.\nAlthough it’s been hard-hit by the deflating of the bubbles that formed earlier this year for meme stocks, special purpose acquisition company&nbsp;(SPAC) stocks and short-squeeze plays, it may still have more room to fall.\nThere may be something that comes about a few weeks from now that enables it to make a move back above $10 per share: lower-than-expected losses.\nThe problem is that it’s murky whether its recent cost control issues are a transitory phenomenon or something that will affect the company further over the next few years.\nCLOV Stock and Its CMS Upgrade\nBefore diving into something that may help Clover in the near future, let’s take a look at the latest news item from the company: anupgrade of its flagship PPO plan&nbsp;by the Centers for Medicare and Medicaid Services (CMS). News of the agency also giving this company the go-ahead to expand its service area is related to this upped rating from CMS.\nAs discussed above, it wasn’t just the company that touted this to the public via a press release. Chamath Palihapitiya, who sponsored the SPAC that took this previously privately-held company public,&nbsp;tweeted about it as well. Both statements appeared to be an attempt to help renew excitement about CLOV stock.\nHowever, while not a negative, this development doesn’t seem that much of a positive. After the upgrade, Clover’s PPO plan now has a 3.5-star rating.\nThat makes it look as if&nbsp;its PPO plans are catching up with the middle of the pack in terms of quality than anything else. Despite Palihapitiya touting it, remember that CMSrates providers on a one-to-five scale.\nInvestors are correct in giving the stock just a small boost on this news. But while this news is by no means a game-changer, there may be something in the weeks ahead that fuels a bona fide rally for this hard-hit name.\nCLOV May Announce Lower-Than-Expected Losses\nAll things considered, you can say few are expecting much out of CLOV stock right now. Analysts are bearish on its fundamentals, and retail traders are waiting for a reason to buy it again.\nWhen they’ll jump back into it is unclear, given how much the meme stock and short-squeeze stock trends have fallen in popularity.\nEven so, there may be something that possibly sends its higher again in the coming weeks. That would be its next earnings report.\nSure, this early-stage company has abig profitability problem. Clover’s MCR, or Medical Care Ratio, has lately come in at above 100%. It’s been paying more out in claims than it has collected in premiums.\nHowever, it may surprise by delivering a lower-than-expected MCR. Over the past few quarters, the company has chalked up its high costs to the post-lockdown “reopening” that followed the vaccine rollout.\nMedical appointments and procedures put on hold in 2020 are getting done in 2021, temporarily skewing the level of Clover’s outlays.\nBut this “pent up” demand may have peaked. The Delta variant outbreak of Covid-19 could also bedelaying treatments/surgeries again.\nWith this, the company may manage to show a much better MCR number in its upcoming results which may be enough to fuel another spike back to $10-$15 per share.\nBottom Line: All Bets Are Off\nThere may be a pathway for Clover stock to bounce back to above $10 per share, but the “lower-than-expected MCR” thesis highlighted above is far from bulletproof. Other factors besides “reopening” demand may be behind the company’s heavy losses.\nAlso, despite having a much lower stock price now than it did a few months back, it’s still richly priced. Growth stocks may have more room to fall, as changes in Fed policy changes make them less appealing.\nIf you strongly believe the company’s heavy losses are transitory, by all means, roll the dice with CLOV stock. But holding&nbsp;off may be the way to go if you think it’ll still have cost control issues or that other risks will continue to weigh down on it.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Health Stock Has an Outside Chance of Suprising in Its Upcoing Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Health Stock Has an Outside Chance of Suprising in Its Upcoing Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-18 21:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/10/clov-stock-has-an-outside-chance-of-suprising-in-its-upcoing-earnings/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nBuying CLOV stock is all about whether you think it can start controlling costs.\n\nClover Health Corp stock has few friends on the “buy” side today.\nAccording to the Wall Street Journal, five analysts ...\n\n<a href=\"https://investorplace.com/2021/10/clov-stock-has-an-outside-chance-of-suprising-in-its-upcoing-earnings/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://investorplace.com/2021/10/clov-stock-has-an-outside-chance-of-suprising-in-its-upcoing-earnings/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114755787","content_text":"Buying CLOV stock is all about whether you think it can start controlling costs.\n\nClover Health Corp stock has few friends on the “buy” side today.\nAccording to the Wall Street Journal, five analysts give shares in the Medicare Advantage provider either a “hold” or “sell” rating, with none of them willing to give it a “buy” rating.\nWorse yet, retail traders haven’t been so keen on it either lately. Even a recent development (which admittedly seems like small potatoes) has failed to give it more than just a slight bump-up in price.\nSo, a lack of Wall Street or Main Street enthusiasm makes it a sell, right? Not exactly.\nAlthough it’s been hard-hit by the deflating of the bubbles that formed earlier this year for meme stocks, special purpose acquisition company (SPAC) stocks and short-squeeze plays, it may still have more room to fall.\nThere may be something that comes about a few weeks from now that enables it to make a move back above $10 per share: lower-than-expected losses.\nThe problem is that it’s murky whether its recent cost control issues are a transitory phenomenon or something that will affect the company further over the next few years.\nCLOV Stock and Its CMS Upgrade\nBefore diving into something that may help Clover in the near future, let’s take a look at the latest news item from the company: anupgrade of its flagship PPO plan by the Centers for Medicare and Medicaid Services (CMS). News of the agency also giving this company the go-ahead to expand its service area is related to this upped rating from CMS.\nAs discussed above, it wasn’t just the company that touted this to the public via a press release. Chamath Palihapitiya, who sponsored the SPAC that took this previously privately-held company public, tweeted about it as well. Both statements appeared to be an attempt to help renew excitement about CLOV stock.\nHowever, while not a negative, this development doesn’t seem that much of a positive. After the upgrade, Clover’s PPO plan now has a 3.5-star rating.\nThat makes it look as if its PPO plans are catching up with the middle of the pack in terms of quality than anything else. Despite Palihapitiya touting it, remember that CMSrates providers on a one-to-five scale.\nInvestors are correct in giving the stock just a small boost on this news. But while this news is by no means a game-changer, there may be something in the weeks ahead that fuels a bona fide rally for this hard-hit name.\nCLOV May Announce Lower-Than-Expected Losses\nAll things considered, you can say few are expecting much out of CLOV stock right now. Analysts are bearish on its fundamentals, and retail traders are waiting for a reason to buy it again.\nWhen they’ll jump back into it is unclear, given how much the meme stock and short-squeeze stock trends have fallen in popularity.\nEven so, there may be something that possibly sends its higher again in the coming weeks. That would be its next earnings report.\nSure, this early-stage company has abig profitability problem. Clover’s MCR, or Medical Care Ratio, has lately come in at above 100%. It’s been paying more out in claims than it has collected in premiums.\nHowever, it may surprise by delivering a lower-than-expected MCR. Over the past few quarters, the company has chalked up its high costs to the post-lockdown “reopening” that followed the vaccine rollout.\nMedical appointments and procedures put on hold in 2020 are getting done in 2021, temporarily skewing the level of Clover’s outlays.\nBut this “pent up” demand may have peaked. The Delta variant outbreak of Covid-19 could also bedelaying treatments/surgeries again.\nWith this, the company may manage to show a much better MCR number in its upcoming results which may be enough to fuel another spike back to $10-$15 per share.\nBottom Line: All Bets Are Off\nThere may be a pathway for Clover stock to bounce back to above $10 per share, but the “lower-than-expected MCR” thesis highlighted above is far from bulletproof. Other factors besides “reopening” demand may be behind the company’s heavy losses.\nAlso, despite having a much lower stock price now than it did a few months back, it’s still richly priced. Growth stocks may have more room to fall, as changes in Fed policy changes make them less appealing.\nIf you strongly believe the company’s heavy losses are transitory, by all means, roll the dice with CLOV stock. But holding off may be the way to go if you think it’ll still have cost control issues or that other risks will continue to weigh down on it.","news_type":1},"isVote":1,"tweetType":1,"viewCount":350,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":33,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/850176352"}